Q&A: Suzanne Topalian on Immune Therapies

Autor:	Suzanne Topalian
Rok vydání:	2013
Předmět:	Oncology medicine.medical_specialty business.industry Melanoma education Cancer medicine.disease humanities Immune therapy Internal medicine medicine business health care economics and organizations
Zdroj:	Cancer Discovery. 3:712-712
ISSN:	2159-8290 2159-8274
DOI:	10.1158/2159-8290.cd-nd2013-016
Popis:	Suzanne Topalian, MD, professor of surgery and oncology and director of the melanoma program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, MD, discusses progress with drugs that inhibit immune-checkpoint receptors and ligands, including PD-1 and PD-L1 inhibitors.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c24f385bcccc2a61193d579cd82f40cf https://doi.org/10.1158/2159-8290.cd-nd2013-016 Zobrazit plný text záznamu